• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TIROFIBAN Drug Record

  • Summary
  • Interactions
  • Claims
  • TIROFIBAN chembl:CHEMBL916 Approved

    Alternate Names:

    TIROFIBAN
    AGGRASTAT
    MK-383
    L-700462
    N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDYL)BUTYL]-L-TYROSINE
    (2S)-2-(BUTYLSULFONYLAMINO)-3-[4-(4-PIPERIDIN-4-YLBUTOXY)PHENYL]PROPANOIC ACID
    drugbank:00775
    pubchem.compound:60947
    chemidplus:144494-65-5
    rxcui:73137
    chembl:CHEMBL916

    Drug Info:

    Year of Approval 1998
    Drug Class platelet aggregation inhibitors
    FDA Approval 1998
    Drug Class small molecule
    Drug Indications Platelet Aggregation Inhibitors
    (1 More Sources)

    Publications:

    Juwana et al., 2010, Tirofiban for myocardial infarction., Expert Opin Pharmacother
    Roffi et al., 2002, Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up., Circulation
    Kondo et al., 2002, Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab., Clin Pharmacokinet
    Dickfeld et al., 2001, Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists., Thromb. Res.
    von Segesser et al., 2001, Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass., Perfusion
    Théroux et al., 2000, Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study., Circulation
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
  • TIROFIBAN   ITGA2B

    Interaction Score: 13.74

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    20210689 12057986 11929319 11342206 11565896 11076818 20938371


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • TIROFIBAN   ITGB3

    Interaction Score: 6.18

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    20938371 10592235 20210689 11752352


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • TIROFIBAN   FGG

    Interaction Score: 4.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • TIROFIBAN   FGB

    Interaction Score: 3.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • TIROFIBAN   FGA

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • TEND: TIROFIBAN

    • Version: 01-August-2011

    Alternate Names:
    TIROFIBAN Primary Drug Name

    Drug Info:
    Drug Class platelet aggregation inhibitors
    Year of Approval 1998

    Publications:

  • TdgClinicalTrial: TIROFIBAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Platelet Aggregation Inhibitors
    Drug Class small molecule
    FDA Approval 1998

    Publications:

  • PharmGKB: tirofiban

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics

  • TTD: Tirofiban

    • Version: 2020.06.01

    Alternate Names:
    D0BN9X TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL916

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21